Editorial: Stem cell follies: Crank up the spin machine
By Sacramento Bee,
Sacramento Bee
| 07. 17. 2005
Just a half year into its troubled existence, California's stem cell research institute has already spent more than $2 million, none of it on research. Alert members of the institute's 29-member oversight board are starting to ask an important question: Where the heck is this money going?
Despite a cash-flow shortage caused by a pair of costly lawsuits, institute chairman Robert Klein II has been spending freely. Four months ago, under Klein's direction, the institute quietly hired Edelman, which bills itself as the "world's largest independent public relations group," at a rate of $27,550 a month. Edelman replaced Redgate Communications, which had already racked up $108,000 in PR work in three months.
Klein didn't use a competitive bidding process in retaining either of these companies. Neither did he seek competitive bids before he hired the law firm of Remcho, Johansen & Purcell for $320,000. At the moment, he and institute President Zach Hall are negotiating a long-term contract with Edelman that could top $500,000.
Oversight board members learned of these expenditures at a meeting in Irvine last Tuesday, and some...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...